Literature DB >> 12824800

Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission.

Marina Giuliano1, Lucia Palmisano, Clementina M Galluzzo, Roberta Amici, Elena Germinario, Pius Okong, Praxedes Kituuka, Francis Mmirro, Michele Magoni, Stefano Vella.   

Abstract

Two zidovudine/lamivudine regimens for the prevention of HIV perinatal transmission were studied for the selection of resistance mutations. The M184V mutation was detected one week after delivery in six out of fifty women (12%) who received the regimen prepartum, intrapartum and postpartum, and was no longer present 3 months later. No nucleoside reverse transcriptase inhibitor resistance-associated mutations were detected in 50 women who received zidovudine/lamivudine intrapartum and postpartum only. No association with the risk of perinatal transmission was found.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12824800     DOI： 10.1097/00002030-200307040-00022

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  8 in total

1.  Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.

Authors:  François Dabis; Laurence Bequet; Didier Koumavi Ekouevi; Ida Viho; François Rouet; Apollinaire Horo; Charlotte Sakarovitch; Renaud Becquet; Patricia Fassinou; Laurence Dequae-Merchadou; Christiane Welffens-Ekra; Chrisitine Rouzioux; Valériane Leroy
Journal:  AIDS       Date:  2005-02-18       Impact factor: 4.177

2.  Vertical transmission of HIV-an update.

Authors:  Mamatha M Lala; Rashid H Merchant
Journal:  Indian J Pediatr       Date:  2010-09-03       Impact factor: 1.967

3.  No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.

Authors:  Sajini Souda; Simani Gaseitsiwe; Nathan Georgette; Kathleen Powis; Daisy Moremedi; Thato Iketleng; Jean Leidner; Claire Moffat; Anthony Ogwu; Shahin Lockman; Sikhulile Moyo; Mompati Mmalane; Rosemary Musonda; Joseph Makhema; Max Essex; Roger Shapiro
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

Review 4.  Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.

Authors:  Carlo Giaquinto; Osvalda Rampon; Anita De Rossi
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs.

Authors:  Luis E Soto-Ramirez; Roberto Rodriguez-Diaz; Adriana S Durán; Marcelo H Losso; Horacio Salomón; Manuel Gómez-Carrillo; Sandra Pampuro; D Robert Harris; Geraldo Duarte; Ricardo S De Souza; Jennifer S Read
Journal:  AIDS Res Hum Retroviruses       Date:  2008-06       Impact factor: 2.205

Review 6.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

7.  Prevention on parent to child transmission of HIV - what is new?

Authors:  Mamatha M Lala; Rashid H Merchant
Journal:  Indian J Pediatr       Date:  2012-10-19       Impact factor: 1.967

8.  Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response.

Authors:  Vlada V Melekhin; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Gema Barkanic; Stephen P Raffanti; Timothy R Sterling
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.